Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects 18 to 55 years of age, inclusive.~* Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2 and a minimum weight of at least 50.0 kg~* Current recreational polydrug users who self-report to:~  * Have used stimulants (e.g., amphetamines, cocaine, methylphenidate) for non-therapeutic purposes (i.e., for psychoactive effects) at least 10 times in the past year and at least 1 time in the 8 weeks before Screening.~ * Have at least 10 lifetime uses of drugs (e.g., opioids, sedatives) from at least 1 other class other than alcohol.~* Agree to use an approved method of contraception~* Be willing and able to abide by all study requirements and restrictions~* Additional criteria may apply~Exclusion Criteria:~* Substance or alcohol dependence within the past 2 years,~* Clinically significant medical history or illness~* Female subjects who have a positive pregnancy test, are currently pregnant or lactating, or who are planning to become pregnant within 30 days of last study drug administration.~* Donation or loss of more than 500 mL whole blood within 30 days preceding the Screening visit.~* Additional criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): Placebo oral tablet and Placebo oral capsule
- Treatment B (Type: EXPERIMENTAL): Tozadenant 120 mg
- Treatment C (Type: EXPERIMENTAL): Tozadenant 240 mg
- Treatment D (Type: EXPERIMENTAL): Tozadenant 480 mg
- Treatment E (Type: ACTIVE_COMPARATOR): d-amphetamine 20 mg
- Treatment F (Type: ACTIVE_COMPARATOR): d-amphetamine 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).